Zealand Pharma Inventory 2017-2024 | ZLDPF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zealand Pharma inventory from 2017 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zealand Pharma inventory from 2017 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$140.4B
Bristol Myers Squibb (BMY)	$114.2B
Gilead Sciences (GILD)	$113.5B
Vertex Pharmaceuticals (VRTX)	$102.1B
CSL (CSLLY)	$83.7B
Regeneron Pharmaceuticals (REGN)	$77.8B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$37.8B
Alnylam Pharmaceuticals (ALNY)	$30.8B
BioNTech SE (BNTX)	$26.5B
Biogen (BIIB)	$21.5B
Illumina (ILMN)	$21.3B
BeiGene (BGNE)	$17B
Moderna (MRNA)	$15.2B
Genmab (GMAB)	$13.3B
Incyte (INCY)	$12.9B
Insmed (INSM)	$12.4B
BioMarin Pharmaceutical (BMRN)	$12.4B
Sarepta Therapeutics (SRPT)	$11.4B
Bio-Techne Corp (TECH)	$11.3B
Vaxcyte (PCVX)	$10.7B
Exact Sciences (EXAS)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.2B
QIAGEN (QGEN)	$10.1B
Exelixis (EXEL)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8.2B